NLRC4 and adult-onset Still disease: Two clinical trials evaluated the effect of IL-18 inhibition using IL-18BP in adult-onset Still’s disease and NLRC4-related macrophage activation syndrome (ClinicalTrials.gov Identifier: NCT02398435, NCT03113760) [37,38].